Safeguarding against Ebola: Vaccines and therapeutics to be stockpiled for future outbreaks.

about

Safeguarding against Ebola: Vaccines and therapeutics to be stockpiled for future outbreaks.

Item

http://www.wikidata.org/entity/Q55026054

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Safeguarding against Ebola: Va ...... ockpiled for future outbreaks.

@en

Safeguarding against Ebola: Va ...... ockpiled for future outbreaks.

@nl

type

Item

label

Safeguarding against Ebola: Va ...... ockpiled for future outbreaks.

@en

Safeguarding against Ebola: Va ...... ockpiled for future outbreaks.

@nl

prefLabel

Safeguarding against Ebola: Va ...... ockpiled for future outbreaks.

@en

Safeguarding against Ebola: Va ...... ockpiled for future outbreaks.

@nl

P1476

Safeguarding against Ebola: Va ...... tockpiled for future outbreaks

@en

P2093

Chia-Wei Tsai

http://www.w3.org/2001/XMLSchema#string

Gary L Disbrow

http://www.w3.org/2001/XMLSchema#string

P2860

Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 Days

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)

Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.

A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection

Federal funding in support of Ebola medical countermeasures R&D

Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule.

Development of vaccines for prevention of Ebola virus infection.

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.

Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 Year.

Challenges, progress, and opportunities: proceedings of the filovirus medical countermeasures workshop.

P304

e0006275

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PNTD.0006275

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Eric M Espeland

Joseph Larsen

P577

2018-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29621257

http://www.w3.org/2001/XMLSchema#string

P921

Ebola virus

stockpiling

P932

5886391

http://www.w3.org/2001/XMLSchema#string